MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.

ABSTRACT:

Background

Despite the unprecedented success of ibrutinib in lymphoma therapy, the development of ibrutinib resistance due to acquired BTK or PLCγ2 mutations has become a new clinical problem. However, not all resistance is mediated by these mutations and these mechanisms are poorly understood due to a lack of study tools that truly recapitulate this clinical scenario.

Methods

We established a novel patient-derived ibrutinib-resistant mantle cell lymphoma (MCL) line named MCIR1. Using immunological, molecular, and cytogenetic approaches, we comprehensively characterized MCIR1 and further demonstrated its utility in the study of resistance mechanisms and treatments to overcome this resistance.

Results

We show that MCIR1 is a bona fide ibrutinib-resistant MCL cell line

SUBMITTER: Wu X 

PROVIDER: S-EPMC8654320 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature